271542 Staying Alive on the Outside: Opioid Overdose Prevention and Response for People Leaving Prison

Tuesday, October 30, 2012 : 1:02 PM - 1:06 PM

Traci Green, PhD , Department of General Internal Medicine, Rhode Island Hospital, Providence, RI
Each year, more than half a million men and women in America are released from prison or jail. The first two weeks following release is associated with a 129 times increased risk of death by drug overdose, often due to a loss of tolerance during incarceration. However, a bystander can reverse opioid overdose using rescue breathing and Naloxone, an opioid antagonist drug. This video teaches viewers to prevent and recognize opioid overdoses, and how to intervene when they happen. Through interviews, conversation, and model training sessions, Rhode Island harm reduction community members candidly discuss the challenges of reentry from prison, opioid addiction and relapse, and misconceptions about opioid tolerance and overdose. Viewers learn strategies to avoid overdose while using opioids, and what to do if they witness an overdose. The educational focus is on Naloxone dose assembly and administration, with engaging, clear demonstrations of both intranasal and intramuscular dose administration. Viewers are encouraged to think about the possibility of overdose happening to them or to someone around them, and to plan for both situations, including strategies for calling 911, post-reversal care, and overdose planning with a friend or family member. The video is meant to accompany Naloxone distribution, either in release planning at a correctional facility, or in the community.

Learning Areas:
Implementation of health education strategies, interventions and programs

Learning Objectives:
Identify risk factors and symptoms of opioid overdose. Explain protocol for responding to opioid overdose, including Naloxone assembly and administration, rescue breathing, and calling 911. Discuss overdose risks and issues specific to prison reentry populations.

Keywords: Drug Abuse, Prison

Presenting author's disclosure statement:
Organization/institution whose products or services will be discussed: The researchers have an Investigational New Drug Application with the FDA to prescribe and dispense intra-nasal Naloxone to participants in the overdose prevention and response program associated with this video.

Qualified on the content I am responsible for because: I am principal investigator on the NIDA-funded study supporting this research and video production project. I am a drug abuse epidemiologist with research expertise in opioid overdose and drug-related injury prevention.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 4215.0: US Film Festival Session 2